NewLink nets $20M Ebola milestone from Merck

NewLink's ($NLNK) Ebola vaccine tie-up with Merck ($MRK) continues to pay off. The Iowa-based company has triggered a milestone payment from the pharma giant worth $20 million, it said last week, and it'll put the money back into its vaccine work for infectious diseases. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.